Re-entered obesity through M&A after danuglipron failed. Acquired Metsera November 2025 for about $7.3B upfront plus up to $3.5B in contingent milestones (up to about $10B headline) for an oral and injectable GLP-1 pipeline. Sciwind partnership for ecnoglutide in China ($495M).